CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top Player Positioning
3.2.3.Porter's five forces analysis

3.3.Patent Analysis
3.4.Value chain analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in demand for HCQ as potential treatment source amidst pandemic
3.5.1.2.Increase in cases of malaria

3.5.2.Restraint

3.5.2.1.Several side-effects of the medicine
3.5.2.2.Ban from several countries owing to lacking study data
3.5.2.3.Ongoing research and positive results of other drugs for potential cure

3.5.3.Opportunity

3.5.3.1.Repurposing hydroxychloroquine as anti-cancer drug

3.6.Impact of CORONA (COVID 19) outbreak on global hydroxychloroquine market

CHAPTER 4:HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Tablet

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region

4.3.Active pharmaceutical ingredient

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region

CHAPTER 5:HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital pharmacy

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region

5.3.Retail pharmacy

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region

5.4.Online pharmacy

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region

5.5.Specialty drug store

5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region

CHAPTER 6:HYDROXYCHLOROQUINE MARKET, BY DISEASES

6.1.Overview

6.1.1.Market size and forecast

6.2.Malaria

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region

6.3.Rheumatoid arthritis

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region

6.4.Lupus Erythematosus

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region

6.5.Coronavirus

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by region

6.6.Others

6.6.1.Key market trends, growth factors, and opportunities
6.6.2.Market size and forecast, by region

CHAPTER 7:HYDROXYCHLOROQUINE MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by product type
7.2.3.Market size and forecast, by distribution channel
7.2.4.Market size and forecast, by disease
7.2.5.Market share analysis, by country
7.2.6.U.S.

7.2.6.1.Market size and forecast, by product type
7.2.6.2.Market size and forecast, by distribution channel
7.2.6.3.Market size and forecast, by disease

7.2.7.Canada

7.2.7.1.Market size and forecast, by product type
7.2.7.2.Market size and forecast, by distribution channel
7.2.7.3.Market size and forecast, by disease

7.2.8.Mexico

7.2.8.1.Market size and forecast, by product type
7.2.8.2.Market size and forecast, by distribution channel
7.2.8.3.Market size and forecast, by disease

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by product type
7.3.3.Market size and forecast, by distribution channel
7.3.4.Market size and forecast, by disease
7.3.5.Market share analysis, by country
7.3.6.Germany

7.3.6.1.Market size and forecast, by product type
7.3.6.2.Market size and forecast, by distribution channel
7.3.6.3.Market size and forecast, by disease

7.3.7.France

7.3.7.1.Market size and forecast, by product type
7.3.7.2.Market size and forecast, by distribution channel
7.3.7.3.Market size and forecast, by disease

7.3.8.UK

7.3.8.1.Market size and forecast, by product type
7.3.8.2.Market size and forecast, by distribution channel
7.3.8.3.Market size and forecast, by disease

7.3.9.Italy

7.3.9.1.Market size and forecast, by product type
7.3.9.2.Market size and forecast, by distribution channel
7.3.9.3.Market size and forecast, by disease

7.3.10.Spain

7.3.10.1.Market size and forecast, by product type
7.3.10.2.Market size and forecast, by distribution channel
7.3.10.3.Market size and forecast, by disease

7.3.11.Rest of Europe

7.3.11.1.Market size and forecast, by product type
7.3.11.2.Market size and forecast, by distribution channel
7.3.11.3.Market size and forecast, by disease

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by product type
7.4.3.Market size and forecast, by distribution channel
7.4.4.Market size and forecast, by disease
7.4.5.Market share analysis, by country
7.4.6.China

7.4.6.1.Market size and forecast, by product type
7.4.6.2.Market size and forecast, by distribution channel
7.4.6.3.Market size and forecast, by disease

7.4.7.Japan

7.4.7.1.Market size and forecast, by product type
7.4.7.2.Market size and forecast, by distribution channel
7.4.7.3.Market size and forecast, by disease

7.4.8.India

7.4.8.1.Market size and forecast, by product type
7.4.8.2.Market size and forecast, by distribution channel
7.4.8.3.Market size and forecast, by disease

7.4.9.Australia

7.4.9.1.Market size and forecast, by product type
7.4.9.2.Market size and forecast, by distribution channel
7.4.9.3.Market size and forecast, by disease

7.4.10.South Korea

7.4.10.1.Market size and forecast, by product type
7.4.10.2.Market size and forecast, by distribution channel
7.4.10.3.Market size and forecast, by disease

7.4.11.Rest of Asia-Pacific

7.4.11.1.Market size and forecast, by product type
7.4.11.2.Market size and forecast, by distribution channel
7.4.11.3.Market size and forecast, by disease

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by product type
7.5.3.Market size and forecast, by distribution channel
7.5.4.Market size and forecast, by disease
7.5.5.Market share analysis, by country
7.5.6.Brazil

7.5.6.1.Market size and forecast, by product type
7.5.6.2.Market size and forecast, by distribution channel
7.5.6.3.Market size and forecast, by disease

7.5.7.Saudi Arabia

7.5.7.1.Market size and forecast, by product type
7.5.7.2.Market size and forecast, by distribution channel
7.5.7.3.Market size and forecast, by disease

7.5.8.South Africa

7.5.8.1.Market size and forecast, by product type
7.5.8.2.Market size and forecast, by distribution channel
7.5.8.3.Market size and forecast, by disease

7.5.9.Rest of LAMEA

7.5.9.1.Market size and forecast, by product type
7.5.9.2.Market size and forecast, by distribution channel
7.5.9.3.Market size and forecast, by disease

CHAPTER 8:COMPANY PROFILES:

8.1.Cadila Healthcare Limited

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio
8.1.4.Business performance

8.2.Hikma Pharmaceuticals PLC

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.2.4.Business performance

8.3.IPCA Laboratories Ltd.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Product portfolio
8.3.4.Business performance
8.3.5.Key Developmental strategies

8.4.Mylan N.V.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.4.5.Key Developmental strategies

8.5.Novartis International AG

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.Pfizer Inc.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio
8.6.4.Business performance

8.7.Sanofi S.A.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Product portfolio
8.7.4.Business performance

8.8.Taj Pharma Group

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Product portfolio

8.9.Teva Pharmaceutical Industries Ltd.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.9.4.Business performance

8.10.Torrent Pharmaceuticals Limited

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Business performance